LILLY PROZAC SALES INCREASE 7% TO $580.7 MIL. IN THIRD QUARTER; PFIZER NORVASC SUPPLANTS PROCARDIA XL AS TOP PRODUCT WITH $899.8 MIL. YEAR-TO-DATE
Executive Summary
Lilly's Prozac showed a 7% sales increase for the third quarter, posting $580.7 mil. in worldwide sales for the three months, the company reported Oct. 17
You may also be interested in...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.